Abstract
Treatment with antiretroviral therapy (ART) has greatly reduced the incidence of dementia. The goal of this longitudinal study was to determine if there are ongoing macrostructural brain changes in human immunodeficiency virus—positive (HIV+) individuals treated with ART. To quantify brain structure, three-dimensional T1-weighted magnetic resonance imaging (MRI) scans were performed at baseline and again after 24 months in 39 HIV+ patients on ART and 30 HIV− controls. Longitudinal changes in brain volume were measured using tissue segmentation within regions of interest and deformation morphometry. Measured by tissue segmentation, HIV+ patients on ART had significantly (all P <.05) greater rates of white matter volume loss than HIV− control individuals. Compared with controls, the subgroup of HIV+ individuals on ART with viral suppression also had significantly greater rates of white matter volume loss. Deformation morphometry confirmed these results with more specific spatial localization. Deformation morphometry also detected greater rates of gray matter and white matter loss in the subgroup of HIV+ individuals with detectable viral loads. These results provide evidence of ongoing brain volume loss in HIV+ individuals on stable ART, possibly suggesting ongoing cerebral injury. The presence of continuing injury raises the possibility that HIV+ individuals—even in the presence of viral suppression in the periphery—are at greater risk for future cognitive impairments and dementia and possibly faster cognitive decline. Therefore, HIV+ individuals on ART should be monitored for cognitive decline, and treatments that reduce ongoing neurological injury should be considered.
Similar content being viewed by others
References
Agartz I, Brag S, Franck J, Hammarberg A, Okugawa G, Svinhufvud K, Bergman H (2003). Mr volumetry during acute alcohol withdrawal and abstinence: a descriptive study. Alcohol Alcohol 38: 71–78.
Ances BM, Roc AC, Wang J, Korczykowski M, Okawa J, Stern J, Kim J, Wolf R, Lawler K, Kolson DL, Detre JA (2006). Caudate blood flow and volume are reduced in HIV+ neurocognitively impaired patients. Neurology 66: 862–866.
Aylward EH, Henderer JD, McArthur JC, Brettschneider PD, Harris GJ, Barta PE, Pearlson GD (1993). Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. Neurology: 2099–2104.
Berman S, O’Neill J, Fears S, Bartzokis G, London ED (2008). Abuse of amphetamines and structural abnormalities in the brain. Ann N Y Acad Sci 1141: 195–220.
Cardenas VA, Studholme C, Gazdzinski S, Durazzo TC, Meyerhoff DJ (2007). Deformation-based morphometry of brain changes in alcohol dependence and abstinence. Neuroimage 34: 879–887.
Cardenas VA, Studholme C, Meyerhoff DJ, Song E, Weiner MW (2005). Chronic active heavy drinking and family history of problem drinking modulate regional brain tissue volumes. Psychiatry Res 138: 115–130.
Chang L, Ernst T, Witt MD, Ames N, Walot I, Jovicich J, DeSilva M, Trivedi N, Speck O, Miller EN (2003). Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. Antivir Ther 8: 17–26.
Chao LL, Cardenas VA, Meyerhoff DJ, Rothlind JC, Flenniken DL, Lindgren JA, Weiner MW (2003). Abnormal contingent negative variation in HIV patients receiving antiretroviral therapy. Neuroreport 14: 2111–2115.
Chui HC (2000). Vascular dementia, a new beginning: shifting focus from clinical phenotype to ischemic brain injury. In: Neurologic clinics of North America. De Kosky ST (ed). Philadelphia: WB Saunders, J Neurol Clin 18: 951–978.
Di Sclafani V, Mackay RD, Meyerhoff DJ, Norman D, Weiner MW, Fein G (1997). Brain atrophy in HIV infection is more strongly associated with CDC clinical stage than with cognitive impairment. J Int Neuropsychopharmacol Soc 3: 276–287.
Ellis R, Langford D, Masliah E (2007). HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 8: 33–44.
Fein G, Di Sclafani V, Meyerhoff DJ (2002). Prefrontal cortical volume reduction associated with frontal cortex function deficit in 6-week abstinent crackcocaine dependent men. Drug Alcohol Depend 68: 87–93.
Fortin C, Joly V (2004). Efavirenz for HIV-1 infection in adults: an overview. Expert Rev Anti Infect Ther 2: 671–84.
Gallo RC, Montagnier L (2003). The discovery of HIV as the cause of AIDS. N Engl J Med 349: 2283–2285.
Hestad K, McArthur JH, Pan GJD, Selnes OA, Nance-Sproson TE, Aylward E, Mathews VP, McArthur JC (1993). Regional brain atrophy in HIV-1 infection: association with specific neuropsychological test performance. Acta Neurol Scand 88: 112–118.
Hsue PY, Giri K, Erickson S, MacGregor JS, Younes N, Shergill A, Waters DD (2004). Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 109: 316–319.
Jernigan TJ, Archibald S, Hesselink JR, Atkinson JH, et al (1993). Magnetic resonance imaging morphometric analysis of cerebral volume loss in human immunodeficiency virus infection. Arch Neurol 50: 250–255.
Lim KO, Wozniak JR, Mueller BA, Franc DT, Specker SM, Rodriguez CP, Silverman AB, Rotrosen JP (2008). Brain macro structural and micro structural abnormalities in cocaine dependence. Drug Alcohol Depend 92: 164–172.
Matochik JA, Eldreth DA, Cadet JL, Bolla KI (2005). Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend 77: 23–30.
Meyerhoff D (2001a). Examining the link between alcohol and HIV/AIDS: studies of CNS effects. Alcohol Res Health 25: 288–298.
Meyerhoff D, Cardenas V, Song E, Truran D, Blumenfeld R, Ezekiel F, Studholme C, Rothlind JC, Lindgren JA, Weiner M (2003a). Brain morphologic changes suggest persistent brain injury in treated HIV-seropositive patients. In: ISMRM: Toronto. Proc Intl Soc Mag Reson Med 11: p. 278.
Meyerhoff DJ (2001b). Effects of alcohol and HIV infection on the central nervous system. Alcohol Res Health 25: 288–298.
Meyerhoff DJ, Cardenas V, Studholme C, Blumenfeld R, Truran D, Ezekiel F, Lampiris H, Rothlind J, Lindgren J, Weiner MW (2003b). Evidence for brain damage in treated HIV-infected individuals. Neurology 60: A186.
Neuenburg JK, Brodt HR, Herndier BG, Bickel M, Bacchetti P, Price RW, Grant RM, Schlote W (2002). HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 31: 171–177.
Neuenburg JK, Furlan S, Bacchetti P, Price RW, Grant RM (2005). Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy. AIDS 19: 1351–1359.
Nichols TE, Holmes AP (2002). Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp 15: 1–25.
O’Neill J, Cardenas VA, Meyerhoff DJ (2001). Separate and interactive effects of cocaine and alcohol dependence on brain structures and metabolites: quantitative MRI and proton MR spectroscopic imaging. Addict Biol 6: 347–361.
Osborne A (1994). Diagnostic neuroradiology. St. Louis: Mosby.
Pan GJD, McArthur JH, Alyward E, Selnes OA, Nance-Sproson TE, Kumar AJ, Mellits ED, McArthur JC (1992). Patterns of cerebral atrophy in HIV-1-infected individuals: results of a quantitative MRI analysis. Neurology 42: 2125–2130.
Pfefferbaum A, Sullivan EV, Mathalon DH, Shear PK, Rosenbloom MJ, Lim KO (1995). Longitudinal changes in magnetic resonance imaging brain volumes in abstinent and relapsed alcoholics. Alcohol Clin Exp Res 19: 1177–1191.
Pinheiro J, Bates D (2000). Mixed-effects models in S and S-PLUS. New York: Springer-Verlag.
Quickfall J, Crockford D (2006). Brain neuroimaging in cannabis use: a review. J Neuropsychiatry Clin Neurosci 18: 318–332.
Raposo G, Moore M, Innes D, Leijendekker R, Leigh-Brown A, Benaroch P, Geuze H (2002). Human macrophages accumulate HIV-1 particles in MHC II compartments. Traffic 3: 718–729.
Roc AC, Ances BM, Chawla S, Korczykowski M, Wolf RL, Kolson DL, Detre JA, Poptani H (2007). Detection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy. Arch Neurol 64: 1249–1257.
Rothlind JC, Greenfield TM, Bruce AV, Meyerhoff DJ, Flenniken DL, Lindgren JA, Weiner MW (2005). Heavy alcohol consumption in individuals with HIV infection: effects on neuropsychological performance. J Int Neuropsychol Soc 11: 70–83.
Schweinsburg BC, Taylor MJ, Alhassoon OM, Gonzalez R, Brown GG, Ellis RJ, Letendre S, Videen JS, McCutchan JA, Patterson TL, Grant I (2005). Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J NeuroVirol 11: 356–364.
Shibuyama S, Gevorkyan A, Yoo U, Tim S, Dzhangiryan K, Scott JD (2006). Understanding and avoiding antiretroviral adverse events. Curr Pharm Des 12: 1075–1090.
Stout JC, Ellis RJ, Jernigan TL, Archibald SL, Abramson I, Wolfson T, McCutchan JA, Wallace MR, Atkinson JH, Grant I (1998). Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. HIV Neurobehavioral Research Center Group. Arch Neurol 55: 161–168.
Studholme C, Drapaca C, Iordanova B, Cardenas V (2006). Deformation based mapping of volume change from serial brain MRI in the presence of local tissue contrast change. IEEE Trans Med Imaging 25: 626–639.
Tanabe J, Tregellas JR, Dalwani M, Thompson L, Owens E, Crowley T, Banich M (2009). Medial orbitofrontal cortex gray matter is reduced in abstinent substance-dependent individuals. Biol Psychiatry 65: 160–164.
Thompson PM, Dutton RA, Hayashi KM, Lu A, Lee SE, Lee JY, Lopez OL, Aizenstein HJ, Toga AW, Becker JT (2006). 3D mapping of ventricular and corpus callosum abnormalities in HIV/AIDS. Neuroimage 31: 12–23.
Thompson PM, Dutton RA, Hayashi KM, Toga AW, Lopez OL, Aizenstein HJ, Becker JT (2005). Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4 + T lymphocyte decline. Proc Natl Acad Sci U S A 102: 15647–1552.
Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, Lee JY, Toga AW, Ling W, London ED (2004). Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 24: 6028–6036.
Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, Giulianelli M, Galgani S, Antinori A, Narciso P (2007). Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 45: 174–182.
Tucker KA, Robertson KR, Lin W, Smith JK, An H, Chen Y, Aylward SR, Hall CD (2004). Neuroimaging in human immunodeficiency virus infection. J Neuroimmunol 157: 153–162.
Worsley KJ, Liao CH, Aston J, Petre V, Duncan GH, Morales F, Evans AC (2002). A general statistical analysis for fMRI data. Neuroimage 15: 1–15.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported in part by NIH grants P01 AA011493, R01 MH65392, and R03 EB 008136 and the Department of Veterans Affairs Research Service.
Rights and permissions
About this article
Cite this article
Cardenas, V.A., Meyerhoff, D.J., Studholme, C. et al. Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. Journal of NeuroVirology 15, 324–333 (2009). https://doi.org/10.1080/13550280902973960
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1080/13550280902973960